milquantel 2.5 mg/25 mg tablettten voor kleine honden en pups die minstens 0,5 kg wegen
krka d.d., novo mesto - milbemycine oxime; praziquantel - tablet - milbemycine oxime 2,5 mg/stuk; praziquantel 25 mg/stuk, - milbemycin oxime, combinations - honden
fiprotec 67 mg spot-on oplossing voor kleine honden
beaphar b.v. - fipronil - spot-on oplossing - fipronil 100 mg/ml, - fipronil - honden
milprazin 4 mg/ 10 mg filmomhulde tabletten voor kleine katten en kittens met een gewicht van ten minste 0,5 kg
krka d.d., novo mesto - milbemycine oxime; praziquantel - filmomhulde tablet - milbemycine oxime 4 mg/stuk; praziquantel 10 mg/stuk, - milbemycin oxime, combinations - katten
milquantel 4 mg/10 mg filmomhulde tabletten voor kleine katten en kittens met een gewicht van ten minste 0,5 kg
krka d.d., novo mesto - milbemycine oxime; praziquantel - filmomhulde tablet - milbemycine oxime 4 mg/stuk; praziquantel 10 mg/stuk, - milbemycin oxime, combinations - katten
dronspot 30 mg/7,5 mg spot-on oplossing voor kleine katten
vetoquinol s.a. - emodepside; praziquantel - spot-on oplossing - emodepside 21,4 mg/ml; praziquantel 85,8 mg/ml, - praziquantel, combinations - katten
combotec 67 mg/60.3 mg spot-on oplossing voor kleine honden
beaphar bv - fipronil; methopreen (s-vorm) - spot-on oplossing - fipronil 67 mg/ml; methopreen (s-vorm) 60,3 mg/ml, - fipronil, combinations - honden
tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastische middelen - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom na voorafgaande chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom na voorafgaande chemotherapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
portrazza
eli lilly nederland b.v. - necitumumab - carcinoom, niet-kleincellige long - antineoplastische middelen - portrazza in combinatie met gemcitabine en cisplatine chemotherapie is geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderde of metastatische epidermale groeifactor receptor (egfr) uitdrukken squamous niet-kleincellige longkanker die niet voorafgaande chemotherapie voor deze aandoening ontvangen.
giotrif
boehringer ingelheim international gmbh - afatinib - carcinoom, niet-kleincellige long - antineoplastische middelen - giotrif als monotherapie is geïndiceerd voor de behandeling ofepidermal groei factor receptor (egfr) tki-naïeve volwassen patiënten met lokaal gevorderde of gemetastaseerde niet-kleincellige longkanker (niet-kleincellig longcarcinoom) met activerende egfr-mutatie(s);lokaal gevorderd of gemetastaseerd niet-kleincellig longcarcinoom van plaveiselcel histologie verloopt op of na de op platina gebaseerde chemotherapie.
vargatef
boehringer ingelheim international gmbh - nintedanib - carcinoom, niet-kleincellige long - antineoplastische middelen - vargatef is geïndiceerd in combinatie met docetaxel voor de behandeling van volwassen patiënten met lokaal gevorderde, gemetastaseerde of lokaal terugkerende niet-kleincellige longkanker (nsclc) van adenocarcinoomtumorhistologie na eerstelijns chemotherapie..